Peptide Library

Human study PLS-00249

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

Other design · Not reported participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesityregistry entry · NCT07505745 (RECRUITING, no results posted, planned enrollment 120)

Design and participants

Design
Other design
Population
Adults with prediabetes, insulin resistance and overweight/obesity (registered conditions).
Conditions
Prediabetes, Insulin Resistance, Overweight/Obesity
Planned enrollment (registry)
120
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

  • MOTS-c (intervention) · mots-c · MOTS-c (MDP), as listed among the registry interventions · Subcutaneous injection · Not reported assigned
  • Placebo (comparator) · Placebo, as listed among the registry interventions · placebo · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Insulin sensitivity

unclear outcome · surrogate · Not specified in the record; implied by the study title.

  • No results reported.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

The authors concluded (paraphrased): No conclusions are available. The study is registered as recruiting and no results have been posted.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

  • other: The registry shows status RECRUITING with has_results false. No outcome data are available to appraise.
  • inadequate randomization: The record lists a placebo arm but does not state that allocation was randomized, how it was done, or whether it was concealed.
  • inadequate blinding: Masking of participants, investigators or outcome assessors is not stated in the stored registry fields.
  • inappropriate endpoint: The titled target, insulin sensitivity, is a surrogate metabolic measure rather than a patient-important outcome.
  • selective reporting: Specific primary and secondary outcomes are not given in the stored registry fields, so results cannot be checked against a prespecified plan.
  • funding or conflicts: No sponsor, funding source or conflict-of-interest information appears anywhere in the record.
  • small or imprecise: Planned enrollment is 120 (estimated), so the sample is modest; actual enrollment is unknown.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

  • Insufficient information to assess Insulin sensitivity, glucose control or body weight

Where each value comes from

  • arms: NCT NCT07505745, registry (interventions field) · extracted by AI (automated, not verified by a person)
  • design: NCT NCT07505745, registry (study_type and phases fields) · extracted by AI (automated, not verified by a person)
  • limitations: NCT NCT07505745, registry (status and has_results fields) · extracted by AI (automated, not verified by a person)
  • outcomes: NCT NCT07505745, title (study title) · extracted by AI (automated, not verified by a person)
  • participants: NCT NCT07505745, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
  • population: NCT NCT07505745, registry (conditions field) · extracted by AI (automated, not verified by a person)

  • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).